{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+the+Gastroesophageal+Junction&page=13", "query": { "condition": "Adenocarcinoma of the Gastroesophageal Junction", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 296, "total_pages": 30, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+the+Gastroesophageal+Junction&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+the+Gastroesophageal+Junction&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T12:22:17.634Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00757172", "title": "Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Esophageal Cancer" ], "interventions": [ { "name": "panitumumab", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2009-01", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-03-11", "last_synced_at": "2026-10-15T12:22:17.634Z", "location_count": 21, "location_summary": "Savannah, Georgia • Chicago, Illinois • Evanston, Illinois + 15 more", "locations": [ { "city": "Savannah", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00757172" }, { "nct_id": "NCT04771520", "title": "Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Locally Advanced Primary Malignant Central Nervous System Neoplasm", "Locally Advanced Sarcoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Primary Malignant Central Nervous System Neoplasm", "Metastatic Sarcoma", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Avapritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-01-20", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-15T12:22:17.634Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04771520" }, { "nct_id": "NCT02082210", "title": "A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Hepatocellular Cancer", "Renal Cell Carcinoma", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Emibetuzumab", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2014-03-07", "completion_date": "2018-01-24", "has_results": true, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-10-15T12:22:17.634Z", "location_count": 4, "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02082210" }, { "nct_id": "NCT05203627", "title": "Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gastric Carcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Telemedicine Visit", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 53, "start_date": "2020-01-21", "completion_date": "2026-10-01", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-15T12:22:17.634Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05203627" }, { "nct_id": "NCT06750185", "title": "Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BNT317 DL1", "type": "BIOLOGICAL" }, { "name": "BNT317 DL2", "type": "BIOLOGICAL" }, { "name": "BNT317 DL3", "type": "BIOLOGICAL" }, { "name": "BNT317 DL4", "type": "BIOLOGICAL" }, { "name": "BNT317 DL5", "type": "BIOLOGICAL" }, { "name": "BNT317 DL6", "type": "BIOLOGICAL" }, { "name": "BNT317 selected DLA", "type": "BIOLOGICAL" }, { "name": "BNT317 selected DLB", "type": "BIOLOGICAL" }, { "name": "SoC chemotherapy 1", "type": "DRUG" }, { "name": "SoC chemotherapy 2", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2025-01-13", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-15T12:22:17.634Z", "location_count": 7, "location_summary": "Louisville, Kentucky • Grand Rapids, Michigan • Huntersville, North Carolina + 4 more", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "East Providence", "state": "Rhode Island" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06750185" }, { "nct_id": "NCT02680990", "title": "Resilience and Exercise in Advanced Cancer Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreatic Adenocarcinoma", "Gastric Adenocarcinoma", "Adenocarcinoma of the Gastroesophageal Junction" ], "interventions": [ { "name": "Band Together", "type": "BEHAVIORAL" }, { "name": "Exercise Education", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2015-12", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2018-02-28", "last_synced_at": "2026-10-15T12:22:17.634Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02680990" }, { "nct_id": "NCT07529808", "title": "Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastric Adenocarcinoma", "Gastric (Stomach) Cancer", "Gastroesophageal Adenocarcinoma", "Gastroesophageal Cancer (GC)", "Gastroesophageal Junction (GEJ) Adenocarcinoma", "Gastroesophageal Junction (GEJ) Cancer", "Gastrointestinal Cancer Metastatic", "Gastrointestinal Adenocarcinoma", "Gastrointestinal Cancers", "Colorectal (Colon or Rectal) Cancer", "Pancreatic Cancer", "CDH17-positive Advanced Solid Tumors", "Advanced Gastric Cancer" ], "interventions": [ { "name": "BHB810", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BigHat Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2026-07-16", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-15T12:22:17.634Z", "location_count": 3, "location_summary": "Duarte, California • Santa Monica, California • Fairfax, Virginia", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07529808" }, { "nct_id": "NCT00004235", "title": "Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2000-01", "completion_date": "2004-08", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-10-15T12:22:17.634Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004235" }, { "nct_id": "NCT06764875", "title": "A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2-positive Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 840, "start_date": "2025-03-01", "completion_date": "2030-12-09", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-15T12:22:17.634Z", "location_count": 58, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Duarte, California + 51 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06764875" }, { "nct_id": "NCT04314401", "title": "National Cancer Institute \"Cancer Moonshot Biobank\"", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Myeloid Leukemia", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Esophageal Carcinoma", "Fallopian Tube Carcinoma", "Gastric Carcinoma", "Hormone Receptor-Positive Breast Carcinoma", "Invasive Breast Carcinoma", "Lung Non-Small Cell Carcinoma", "Lung Small Cell Carcinoma", "Malignant Solid Neoplasm", "Melanoma", "Metastatic Prostate Carcinoma", "Multiple Myeloma", "Ovarian Carcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Primary Peritoneal Carcinoma", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Medical Chart Review", "type": "OTHER" }, { "name": "Paracentesis", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 1600, "start_date": "2020-11-11", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-15T12:22:17.634Z", "location_count": 147, "location_summary": "Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 115 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" }, { "city": "Kingman", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04314401" } ] }